Contemporary surgical treatment of advanced-stage melanoma

Archives of Surgery

Volumn 139, Issue 9, 2004, Pages 961-967

  Essner, Richard ^a   Lee, Jonathan H ^a   Wanek, Leslie A ^a   Itakura, Hitoe ^a   Morton, Donald L ^a   Coats, Roy E ^a   Wong, Jan H ^b   Leong, Stanley P L ^b   Goodnight Jr , James E ^b  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b John Wayne Cancer Institute ^*

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; ARTICLE; CANCER CENTER; CANCER SURGERY; CANCER SURVIVAL; COHORT ANALYSIS; DATA BASE; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; METASTASIS; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; SKIN METASTASIS; SURVIVAL RATE; SURVIVAL TIME;

ADULT; AGED; CHI-SQUARE DISTRIBUTION; COHORT STUDIES; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SURVIVAL ANALYSIS;

EID: 4444370752     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.139.9.961     Document Type: Article

References (48)

1. Jemal A, Tiwari RC, Murray T, et al. Cancer statistics, 2004. CA Cancer J Clin. 2004;54:8-29.
2. Legha SS, Ring S, Papadopoulos N, et al. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989;64:2024-2029.
3. McClay EF, Mastrangelo MJ, Berd D, et al. Effective combination chemo/hormonal therapy for malignant melanoma: experience with three consecutive trials. Int J Cancer. 1992;50:553-556.
4. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105-2116.
5. Rosenberg SA, Lotze MT, Yang JC, et al. Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol. 1989;7:1863-1874.
6. Norris W. Eight Cases of Melanosis With Pathological and Therapeutic Remarks on That Disease. London, England: Longman, Brown, Green, Longman, and Roberts; 1857.
7. Snow H. Melanotic cancerous disease. Lancet. 1892;2:872-874.
8. Handley WS. The pathology of melanotic growths in relation to their operative treatment. Lancet. 1907;1:927-996.
9. Recurrence of a melanotic tumor: removal. Lancet. 1851;1:622-623.
10. Wornom IL, Smith JW, Soong SJ, et al. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg. 1986;204:181-185.
11. Feun LG, Gutterman J, Burgess MA, et al. The natural history of resectable metastatic melanoma (stage IVA melanoma). Cancer. 1982;50:1656-1663.
12. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001;19:3622-3634.
13. Weiss M, Loprinzi CL, Cregan ET, Dalton RJ, Novotny P, O'Fallon JR. Utility of follow-up tests for detecting recurrent disease in patients with malignant melanomas. JAMA. 1995;274:1703-1705.
14. Buzaid AC, Tinoco L, Ross MI, Legha SS, Benjamin RS. Role of computed tomography in the staging of patients with local-regional metastases of melanoma. J Clin Oncol. 1995;13:2104-2108.
15. Holder WD Jr, White RL Jr, Zuger JH, Easton EJ Jr, Greene FL. Effectiveness of positron emission tomography for the detection of melanoma metastases. Ann Surg. 1998;227:764-771.
16. Schwimmer J, Essner R, Patel A, et al. A review of the literature for whole-body FDG PET in the management of patients with melanoma. Q J Nucl Med. 2000; 44:153-167.
17. Wong JH, Skinner KA, Kim KA, et al. The role of surgery in the treatment of nonregionally recurrent melanoma. Surgery. 1993;113:389-394.
18. Morton DL, Wanek L, Nizze JA, Elashoff RM, Wong JH. Improved long-term survival after lymphadenectomy of melanoma metastatic to regional nodes: analysis of prognostic factors in 1134 patients from the John Wayne Cancer Clinic. Ann Surg. 1991;214:491-501.
19. Tafra L, Dale PS, Wanek LA, Ramming KP, Morton DL. Resection and adjuvant immunotherapy for melanoma metastatic to the lung and thorax. J Thorac Cardiovasc Surg. 1995;110:119-128.
20. Ollila DW, Essner R, Wanek LA, et al. Surgical resection for melanoma metastatic to the gastrointestinal tract. Arch Surg. 1996;131:975-979.
21. Haigh PI, Essner R, Wardlaw JC, Stern S, Morton DL. Long-term survival after complete resection of melanoma metastatic to the adrenal gland. Ann Surg Oncol. 1999;6:633-639.
22. Rose DM, Essner R, Hughes TMD, et al. Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience. Arch Surg. 2001;136:950-955.
23. Kaplan EL, Meier P. Nonparametric estimates from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
24. Cox DR. Regression model and life tables. J Royal Stat Soc Br. 1972;34:187-220.
25. Legha SS, Ring S, Eton D, et al. Development of a biochemotherapy regimen with concurrent administration of cisplatin, vinblastine, dacarbazine, interferon alfa, and interleukin-2 for patients with metastatic melanoma. J Clin Oncol. 1998; 16:1752-1759.
26. Overett TK, Shiu MH. Surgical treatment of distant metastastic melanoma: indications and results. Cancer. 1985;56:1222-1230.
27. Karakousis CP, Velez A, Driscoll DL, et al. Metastasectomy in malignant melanoma. Surgery. 1994;115:295-302.
28. Joseph WL, Morton DL, Adkins PC. Prognostic significance of tumor doubling time in evaluating operability in pulmonary metastatic disease. J Thorac Cardiovasc Surg. 1971;61:23-32.
29. Barth A, Wanek LA, Morton DL. Prognostic factors in 1521 melanoma patients with distant metastases. J Am Coll Surg. 1995;181:193-201.
30. Lee ML, Tomsu K, Von Eschen KB. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res. 2000;10:81-92.
31. Balch CM, Soong S-J, Murad TM, et al. A multifactorial analysis of melanoma, IV: prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol. 1983;1:126-134.
32. Ollila DW, Hsueh EC, Stern SL, Morton DL. Metastasectomy for recurrent stage IV melanoma. J Surg Oncol. 1999;71:209-213.
33. Paget S. Distribution of secondary growths in cancer of the breast. Lancet. 1889; 1:571.
34. Ewing J. A Treatise on Tumors. 3rd ed. Philadelphia, Pa: WB Saunders; 1928.
35. Zetter BR. The cellular basis of site-specific tumor metastasis. N Engl J Med. 1990;322:605-612.
36. Folkman J. Tumor angiogenesis. In: Holland JF, Frei E, Bast RC, et al, eds. Cancer Medicine. Baltimore, Md: Williams & Wilkins; 1997:181-206.
37. Liotta LA, Kohn EC. Invasion and metastasis. In: Holland JF, Frei E, Bast RC, et al, eds. Cancer Medicine. Baltimore, Md: Williams & Wilkins; 1997:165-180.
38. Roth JA, Grimm EA, Osborne BA, et al. Suppressive immunoregulatory factors produced by tumors. Lymphokine Res. 1983;2:67-73.
39. Avradopoulos K, Mehta S, Blackinton D, et al. Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck. Ann Surg Oncol. 1997;4:184-190.
40. Hsueh EC, Gupta RK, Yee R, et al. Does endogenous immune response determine the outcome of surgical therapy for metastatic melanoma? Ann Surg Oncol. 2000;7:232-238.
41. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother. 1997;20:165-177.
42. Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg. 1992;216:463-482.
43. Hena MA, Emrich LJ, Nambisan RN, et al. Effect of surgical treatment on stage IV melanoma. Am J Surg. 1987;153:270-275.
44. Meyer T, Merkel S, Goehl J, et al. Surgical therapy for distant metastases of malignant melanoma. Cancer. 2000;89:1983-1991.
45. Gutman H, Hess KR, Kokotsakis JA, et al. Surgery for abdominal metastases of cutaneous melanoma. World J Surg. 2001;25:750-758.
46. de Wilt JH, McCarthy WH, Thompson JF. Surgical treatment of splenic metastases in patients with melanoma. J Am Coll Surg. 2003;197:38-43.
47. Hsueh EC, Gupta RK, Qi K, et al. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol. 1998;16:2913-2920.
48. Mackie RM, Reid R. Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med. 2003;348:567-568.